<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03939806</url>
  </required_header>
  <id_info>
    <org_study_id>CO2019</org_study_id>
    <nct_id>NCT03939806</nct_id>
  </id_info>
  <brief_title>Effects of Oxytocin and Carbetocin on Renal System in Cesarean Sections</brief_title>
  <official_title>Renal Effects of Carbetocin and Oxytocin in Cesarean Section for Preventing Post-partum Haemorrhage: a Prospective Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ufuk University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ufuk University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the renal outcome of patients undergoing elective C/S
      where oxytocin or carbetocin is used for postpartum hemorrhage prophylaxis.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2019</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Urine volume</measure>
    <time_frame>Intraoperative period</time_frame>
    <description>Total amount of intraoperative urine output in milliliters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary sodium</measure>
    <time_frame>Preoperative, Postoperative 2nd, 4th, 24th hours</time_frame>
    <description>The change in urinary sodium content (milligrams) compared to the preoperative period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood sodium</measure>
    <time_frame>Preoperative, Postoperative 2nd, 4th, 24th hours</time_frame>
    <description>The change in blood sodium content (milligrams) compared to the preoperative period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood osmolality</measure>
    <time_frame>Preoperative, Postoperative 2nd, 4th, 24th hours</time_frame>
    <description>The change in blood osmolality compared to the preoperative period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood loss</measure>
    <time_frame>Intraoperative period</time_frame>
    <description>The total volume of intraoperative blood loss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for additional uterotonics</measure>
    <time_frame>Starting from the preoperative period, ending at the 24th postoperative hour</time_frame>
    <description>Total dose (milligrams) of additional uterotonics administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood transfusion</measure>
    <time_frame>Starting from the clamping of the umbilical cord, ending at the 24th postoperative hour</time_frame>
    <description>Total volume (milliliters) of blood transfused</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Postpartum Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Oxytocin</arm_group_label>
    <description>This group will be given 3 IU / 3 ml oxytocin (intravenously) after the clamping of the umbilical cord. Uterine tonus will be assessed after 60 seconds and if it is lower than 7, oxytocin 3 IU / 3 ml will be repeated, up to a maximum of three times. If uterine tonus is still lower than 7, rescue uterotonics such as intramuscular methylergonovine or intravenous misoprostol will be administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carbetocin</arm_group_label>
    <description>This group will be given 100 mcg / 3 ml carbetocin (intravenously) after the clamping of the umbilical cord. If uterine tonus is lower than 7, rescue uterotonics such as intramuscular methylergonovine or intravenous misoprostol will be administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>To be given to Oxytocin group following the clamping of the umbilical cord</description>
    <arm_group_label>Oxytocin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbetocin</intervention_name>
    <description>To be given to Carbetocin group following the clamping of the umbilical cord</description>
    <arm_group_label>Carbetocin</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population consists of term (gestational age greater than 37 weeks) pregnant
        women scheduled to undergo elective cesarean section.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Term (&gt;37 weeks of gestation) uncomplicated pregnant women undergoing elective
             cesarean section

        Exclusion Criteria:

          -  Patients refusing to participate in the study

          -  Complicated pregnancies

          -  Patients with risk factors for postpartum hemorrhage

          -  Contraindications for oxytocin or carbetocin usage

          -  Patients with known renal diseases

          -  Preterm births (&lt;37 weeks of gestation)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gamze S Çağlar, Prof.Dr.</last_name>
    <phone>+903122044000</phone>
    <email>gamzesinem@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Baturay K Kazbek, MD</last_name>
    <phone>+903122044000</phone>
    <email>bkkazbek@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ufuk University Faculty of Medicine Hospital</name>
      <address>
        <city>Ankara</city>
        <state>Balgat</state>
        <zip>06510</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <contact>
      <last_name>Baturay K Kazbek, MD</last_name>
      <phone>+903122044000</phone>
      <email>bkkazbek@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Larciprete G, Montagnoli C, Frigo M, Panetta V, Todde C, Zuppani B, Centonze C, Bompiani A, Malandrenis I, Cirese A, Valensise H. Carbetocin versus oxytocin in caesarean section with high risk of post-partum haemorrhage. J Prenat Med. 2013 Jan;7(1):12-8.</citation>
    <PMID>23741542</PMID>
  </reference>
  <reference>
    <citation>Engstrøm T, Barth T, Melin P, Vilhardt H. Oxytocin receptor binding and uterotonic activity of carbetocin and its metabolites following enzymatic degradation. Eur J Pharmacol. 1998 Aug 21;355(2-3):203-10.</citation>
    <PMID>9760035</PMID>
  </reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 3, 2019</study_first_submitted>
  <study_first_submitted_qc>May 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2019</study_first_posted>
  <last_update_submitted>May 10, 2019</last_update_submitted>
  <last_update_submitted_qc>May 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ufuk University</investigator_affiliation>
    <investigator_full_name>Gamze Sinem Caglar</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postpartum Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
    <mesh_term>Carbetocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>May 18, 2020</submitted>
    <returned>June 3, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

